Topic: manufacturing expansion
Thermo Fisher says it will put $24 million into its Scotland site on top of the $270 million it is investing in production at other sites this year.
Regeneron is humming along on the strength Eylea and Dupixent. Now, it’s expanding its production to keep up with that growth.
Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.
Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid-dose production.
Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.
Aldevron unveiled plans to expand its North Dakota headquarters into a 14-acre campus.
GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.
Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.
Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.
Regeneron is supersizing a campus expansion in New York, investing $800 million and adding 1,500 jobs.